Edward J. Ludwig, a director at Boston Scientific Corp (NYSE:BSX), recently sold a significant portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Ludwig sold 12,000 shares of common stock on February 11, 2025, at an average price of approximately $105.48 per share. This transaction totaled around $1.27 million. The sale comes as the $155.77 billion healthcare equipment company trades near its 52-week high of $107.17, having gained over 39% in the past six months. According to InvestingPro analysis, the stock is currently showing overbought signals, with multiple valuation metrics at elevated levels.
Following the sale, Ludwig retains ownership of 24,398 shares of Boston Scientific. The shares were sold in multiple transactions at prices ranging from $105.47 to $105.55. The filing also noted a separate transaction involving the disposition of 3,000 shares, which did not involve a sale. Unlock deeper insights into BSX’s valuation and 20+ additional exclusive ProTips with an InvestingPro subscription.
In other recent news, Boston Scientific Corporation has been the subject of several analyst upgrades. Stifel analysts increased their price target on the company’s shares from $115.00 to $120.00, maintaining a Buy rating. The revised target follows meetings that left the analysts with a positive outlook on Boston Scientific’s future financial performance, particularly in the company’s high-growth divisions. Similarly, RBC Capital Markets raised their price target on Boston Scientific to $116 from $105, following the company’s strong fourth-quarter performance in 2024 and robust initial guidance for 2025. Truist Securities also showed a positive outlook, raising the price target to $120 from $110, and reaffirming a Buy rating.
Additionally, Mizuho (NYSE:MFG) Securities adjusted its outlook on Boston Scientific, raising the price target to $130 from $110 while maintaining an Outperform rating. This revision comes after the company’s global FARAPULSE sales surpassed the $1 billion mark, and the anticipated presentation of Phase 2 ADVANTAGE AF data in the first half of 2025.
In other company developments, Boston Scientific announced that board member Charles J. Dockendorff will not seek re-election at the upcoming 2025 Annual Meeting of Stockholders. The company’s Board and Nominating and Governance Committee are now evaluating the board’s size and composition following Dockendorff’s departure.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.